Charles River Laboratories International Inc Q1 2018 Big Money Sentiment Better Than Expected, now at 1.13

June 29, 2018 - By Lena Young

Charles River Laboratories International, Inc. (NYSE:CRL) Corporate Logo

“Big money” Positions

In Q1 2018 Charles River Laboratories International Inc (NYSE:CRL) big money sentiment increased to 1.13, according to SEC.gov filings. So its up 0.05, from 2017Q4’s 1.08. 140 investment professionals increased and opened new holdings, while 124 decreased and sold their holdings in Charles River Laboratories International Inc so the sentiment increased. These funds own 44.28 million shares, that’s down from 44.57 million shares in 2017Q4. Funds holding Charles River Laboratories International Inc in top 10 decreased from 2 to 1 for a decrease of 1. 31 Investors Sold All; 93 Reduced Holdings; 96 increased holdings while 44 investment professionals bought holdings.

Biggest Charles River Laboratories International Inc Investors

As of Q1 2018 Channing Capital Management Llc has 2.62% invested in Charles River Laboratories International Inc. Charles River Laboratories International Inc’s shareholder Van Berkom & Associates Inc. owns 613,141 shares as of Q1 2018. Copper Rock Capital Partners Llc reported 301,980 shares. The Illinois-based fund Ariel Investments Llc have invested about 1.66% of the active investment manager’s stock portfolio in Charles River Laboratories International Inc. The Michigan-based fund Norris Perne & French Llp Mi looks positive on Charles River Laboratories International Inc, having 99,543 shares.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide.The firm is valued at $5.40 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).The P/E ratio is 42.52. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

The stock increased 1.32% or $1.47 during the last trading session, touching $112.69.Charles River Laboratories International, Inc. has volume of 53,270 shares. Since June 29, 2017 CRL has risen 12.87% and is uptrending. CRL outperformed by 0.30% the S&P500.

Charles River Laboratories International, Inc. (NYSE:CRL)’s quarterly earnings will be announced on August, 8., Zacks reports. Last year’s earnings per share was $1.29, while now analysts expect change of 13.95 % up from current $1.47 earnings per share. CRL’s profit could be $70.43 million with 19.16 P/E in case $1.47 earnings per share is announced. Analysts at Wall Street see Charles River Laboratories International, Inc.’s 6.52 % EPS growth compared to $1.38 earnings per share for last quarter.

Schwab Charles Invest Management has 302,063 shs. Leavell Mngmt invested 0.06% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). Oregon Employees Retirement Fund holds 17,873 shs. Stone Ridge Asset Management reported 7,140 shs or 0.04% of all its holdings. State Street owns 1.25 million shs or 0.01% of their US capital. Capital Fund Mngmt reported 11,100 shs. Gabelli Funds Limited Com holds 0.02% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL) for 27,000 shs. Congress Asset Mgmt Ma stated it has 831,189 shs or 1.25% of all its holdings. State Of Wisconsin Investment Board invested 0% in Charles River Laboratories International, Inc. (NYSE:CRL). Sei Invs Communications invested 0.07% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). Gam Hldgs Ag holds 5,904 shs or 0.02% of its capital. Jacobs Levy Equity Mgmt invested 0.01% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). Pnc Financial Services Grp Inc Inc holds 24,794 shs or 0% of its capital. Millennium Management holds 0.05% or 355,887 shs in its capital. Alyeska Investment Grp L P, a Illinois-based fund reported 617,804 shs.

Charles River Laboratories International, Inc. registered $11.12 million net activity with 0 insider purchases and 24 sales since January 2, 2018. Another trade for 2,872 shs valued at $312,172 was sold by CHUBB STEPHEN D. On Monday, February 26 $34,620 worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by Smith David Ross. 7,740 shs were sold by MILNE GEORGE M JR, worth $890,100 on Friday, March 9. On Wednesday, February 21 a trade for 2,320 shs valued at $250,741 was made by Barbo William D. $1.08M worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by Girshick Birgit on Tuesday, March 6. MASSARO GEORGE sold $34,665 worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 300 shs on Monday, June 25.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

Total analysts of 10 have positions in Charles River (NYSE:CRL) as follows: 5 rated it a “Buy”, 0 with “Sell” and 5 with “Hold”. The positive are 50%. Since January 19, 2018 according to StockzIntelligence Inc Charles River has 11 analyst reports. On Tuesday, April 24 the stock of Charles River Laboratories International, Inc. (NYSE:CRL) earned “Buy” rating by Jefferies. On Tuesday, February 13 the firm has “Buy” rating by Robert W. Baird given. On Monday, January 22 the rating was downgraded by SunTrust to “Hold”. On Tuesday, February 13 RBC Capital Markets maintained the shares of CRL in report with “Hold” rating. On Wednesday, March 14 the company was maintained by Morgan Stanley. On Wednesday, February 14 the firm has “Buy” rating by SunTrust given. On Friday, June 15 KeyBanc Capital Markets upgraded Charles River Laboratories International, Inc. (NYSE:CRL) to “Overweight” rating. On Friday, April 20 the stock has “Hold” rating by MUFG Securities Americas Inc. On Wednesday, February 14 the firm earned “Overweight” rating by JP Morgan.

For more Charles River Laboratories International, Inc. (NYSE:CRL) news released briefly go to: Benzinga.com, 247Wallst.com, Businesswire.com, Benzinga.com or Benzinga.com. The titles are as follows: “Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade” released on June 15, 2018, “Top Analyst Upgrades and Downgrades: Advanced Micro Devices, Delphi, Domino’s Pizza, Southwest Airlines, Square …” on June 15, 2018, “Charles River Laboratories to Present at Jefferies and William Blair Conferences” with a publish date: June 04, 2018, “The Market In 5 Minutes: Tariffs, NXPI, Powell And More” and the last “Benzinga’s Top Upgrades, Downgrades For June 15, 2018” with publication date: June 15, 2018.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.